Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment (Q26827340)

language of work or name

1 reference

May 2013

1 reference

American Journal of Hematology

published in

1 reference

volume

88

1 reference

issue

5

1 reference

page(s)

416-25

1 reference

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy

cites work

1 reference

Currents concepts on the immunopathology of amyloidosis

21 January 2018

1 reference

Incidence and survival in non-hereditary amyloidosis in Sweden

21 January 2018

1 reference

Pitfalls in the diagnosis of primary amyloidosis

21 January 2018

1 reference

Molecular imaging of amyloidosis: will the heart be the next target after the brain?

21 January 2018

1 reference

Systemic amyloidosis: a challenge for the rheumatologist

21 January 2018

1 reference

Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: a single center experience

21 January 2018

1 reference

Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular an

21 January 2018

1 reference

Cardiac amyloidosis in a patient with multiple myeloma: a case report and review of literature.

21 January 2018

1 reference

Echocardiographic evaluation of cardiac amyloid

21 January 2018

1 reference

Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature

21 January 2018

1 reference

Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect.

21 January 2018

1 reference

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

21 January 2018

1 reference

Prevalence of monoclonal gammopathy of undetermined significance

21 January 2018

1 reference

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

Prevalence and origin of amyloid in kidney biopsies.

21 January 2018

1 reference

Amyloid in endomyocardial biopsies.

21 January 2018

1 reference

Amyloid in bone marrow smears of patients affected by multiple myeloma

21 January 2018

1 reference

Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis

21 January 2018

1 reference

Laryngeal amyloidosis causing hoarseness and airway obstruction

21 January 2018

1 reference

Nodular senile pulmonary amyloidosis: a unique case confirmed by immunohistochemistry, mass spectrometry, and genetic study

21 January 2018

1 reference

The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature

21 January 2018

1 reference

Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins.

21 January 2018

1 reference

Glycosaminoglycans are part of amyloid fibrils: ultrastructural evidence in avian AA amyloid stained with cuprolinic blue and labeled with immunogold.

21 January 2018

1 reference

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

21 January 2018

1 reference

Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue.

21 January 2018

1 reference

Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.

21 January 2018

1 reference

Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis

21 January 2018

1 reference

Cardiac amyloidosis: approaches to diagnosis and management

21 January 2018

1 reference

Prognostic significance of strain Doppler imaging in light-chain amyloidosis.

21 January 2018

1 reference

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

21 January 2018

1 reference

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

21 January 2018

1 reference

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features

21 January 2018

1 reference

Treatment of immunoglobulin light chain amyloidosis

21 January 2018

1 reference

Serum uric acid: novel prognostic factor in primary systemic amyloidosis

21 January 2018

1 reference

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

21 January 2018

1 reference

Treatment of "primary" renal amyloidosis with melphalan.

21 January 2018

1 reference

Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).

21 January 2018

1 reference

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review

21 January 2018

1 reference

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

21 January 2018

1 reference

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement

21 January 2018

1 reference

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

21 January 2018

1 reference

Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis

21 January 2018

1 reference

Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.

21 January 2018

1 reference

Transplantation for amyloidosis

21 January 2018

1 reference

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

21 January 2018

1 reference

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

21 January 2018

1 reference

Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.

21 January 2018

1 reference

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

Amyloidosis: pathogenesis and new therapeutic options.

21 January 2018

1 reference

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

21 January 2018

1 reference

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

21 January 2018

1 reference

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

21 January 2018

1 reference

Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma

21 January 2018

1 reference

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

21 January 2018

1 reference

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

21 January 2018

1 reference

Kidney dysfunction during lenalidomide treatment for AL amyloidosis.

21 January 2018

1 reference

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

21 January 2018

1 reference

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

21 January 2018

1 reference

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease

21 January 2018

1 reference

Bortezomib in the treatment of AL amyloidosis: targeted therapy?

21 January 2018

1 reference

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

21 January 2018

1 reference

Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib

21 January 2018

1 reference

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis

21 January 2018

1 reference

Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation

21 January 2018

1 reference

Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement.

21 January 2018

1 reference

End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases.

21 January 2018

1 reference

Cardiac changes in systemic amyloidosis: Visualisation by magnetic resonance imaging

21 January 2018

1 reference

Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

21 January 2018

1 reference

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

21 January 2018

1 reference

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

21 January 2018

1 reference

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

21 January 2018

1 reference

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

21 January 2018

1 reference

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

21 January 2018

1 reference

Renal Transplantation in Systemic Amyloidosis-Importance of Amyloid Fibril Type and Precursor Protein Abundance

21 January 2018

1 reference

Outcome in Renal AL Amyloidosis After Chemotherapy

21 January 2018

1 reference

Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis

21 January 2018

1 reference

7 January 2021

Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it

1 reference

7 January 2021

Left ventricular hypertrophy: cardiac magnetic resonance may help differentiate amyloidosis from hypertrophic cardiomyopathy

1 reference

7 January 2021

High-Dose Chemotherapy with Autotransplantation in AL Amyloidosis: A Flawed Meta-analysis

1 reference

7 January 2021

1 reference

7 January 2021

Thalidomide: a step forward in the treatment of malignant monoclonal gammopathies.

1 reference

7 January 2021

A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis

1 reference

7 January 2021

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

7 January 2021

Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone

1 reference

7 January 2021

Primary localized cutaneous amyloidosis: a sign of immune dysregulation?

1 reference

7 January 2021

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

1 reference

7 January 2021

I don't know how to treat amyloidosis

1 reference

7 January 2021

Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report

1 reference

7 January 2021

Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response

1 reference

7 January 2021